| Ted A. Harris, Phd, Licensed Psychologist, Inc. | |
|
5691 S Redwood Rd # 16 Taylorsville UT 84123-5322 | |
| (801) 265-3895 | |
| (801) 263-1265 |
| Full Name | Ted A. Harris, Phd, Licensed Psychologist, Inc. |
|---|---|
| Speciality | Psychologist |
| Location | 5691 S Redwood Rd # 16, Taylorsville, Utah |
| Authorized Official Name and Position | Ted A Harris (PSYCHOLOGIST) |
| Authorized Official Contact | 8012653895 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Ted A. Harris, Phd, Licensed Psychologist, Inc. 5691 S Redwood Rd # 16 Taylorsville UT 84123-5322 Ph: (801) 265-3895 | Ted A. Harris, Phd, Licensed Psychologist, Inc. 5691 S Redwood Rd # 16 Taylorsville UT 84123-5322 Ph: (801) 265-3895 |
| NPI Number | 1487768826 |
|---|---|
| Provider Enumeration Date | 08/19/2006 |
| Last Update Date | 11/24/2008 |
| Medicare PECOS PAC ID | 5890608236 |
|---|---|
| Medicare Enrollment ID | O20031111000369 |
News Archive
Naurex Inc., a company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported that data presented at Neuroscience 2010 show that GLYX-13, its clinical-stage candidate for the treatment of depression, shares key mechanistic features associated with the antidepressant efficacy of the NMDA receptor antagonist ketamine.
PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging.
Results from the longest-running trial comparing tamoxifen with the aromatase inhibitor letrozole show unequivocally that letrozole has withstood the test of time and continues to prevent breast cancer recurrences and reduce the risk of death in post-menopausal women with hormone receptor-positive early breast cancer.
Statistics show lung cancer is the leading cause of cancer death in African-Americans, with 21,550 new cases expected to be diagnosed and 16,700 deaths expected this year.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487768826 | NPI | - | NPPES |
| 52806017403001 | Other | UT | BCBS OF UTAH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | 91-116205-2501 (Utah) | Primary |
| Provider Name | Ted A Harris |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1033186382 PECOS PAC ID: 9032022819 Enrollment ID: I20091105000509 |
News Archive
Naurex Inc., a company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported that data presented at Neuroscience 2010 show that GLYX-13, its clinical-stage candidate for the treatment of depression, shares key mechanistic features associated with the antidepressant efficacy of the NMDA receptor antagonist ketamine.
PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging.
Results from the longest-running trial comparing tamoxifen with the aromatase inhibitor letrozole show unequivocally that letrozole has withstood the test of time and continues to prevent breast cancer recurrences and reduce the risk of death in post-menopausal women with hormone receptor-positive early breast cancer.
Statistics show lung cancer is the leading cause of cancer death in African-Americans, with 21,550 new cases expected to be diagnosed and 16,700 deaths expected this year.
› Verified 6 days ago
News Archive
Naurex Inc., a company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported that data presented at Neuroscience 2010 show that GLYX-13, its clinical-stage candidate for the treatment of depression, shares key mechanistic features associated with the antidepressant efficacy of the NMDA receptor antagonist ketamine.
PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging.
Results from the longest-running trial comparing tamoxifen with the aromatase inhibitor letrozole show unequivocally that letrozole has withstood the test of time and continues to prevent breast cancer recurrences and reduce the risk of death in post-menopausal women with hormone receptor-positive early breast cancer.
Statistics show lung cancer is the leading cause of cancer death in African-Americans, with 21,550 new cases expected to be diagnosed and 16,700 deaths expected this year.
› Verified 6 days ago
Janet E. Hooper, Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 5689 S Redwood Rd, #28-2, Taylorsville, UT 84123 Phone: 801-266-4643 Fax: 801-266-4775 | |
Primary Children's Hospital Child Psychology & Psychiatry Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 5770 S 1500 W, Taylorsville, UT 84123 Phone: 801-313-7770 | |
Utah Behavior Services, Inc. Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 6013 S Redwood Rd, Taylorsville, UT 84123 Phone: 801-255-5131 Fax: 801-658-0604 | |
Social Me, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 5460 S Capitol Reef Dr, Taylorsville, UT 84129 Phone: 385-323-1880 | |
Hopeful Beginnings Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 5667 S Redwood Rd Unit 6b, Taylorsville, UT 84123 Phone: 801-979-1351 | |
Another Day Therapy, Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 5663 S Redwood Rd Ofc 14, Taylorsville, UT 84123 Phone: 801-893-7767 | |
Jennes Therapy Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 5693 S Redwood Rd Unit 13, Taylorsville, UT 84123 Phone: 385-269-0418 |